论文部分内容阅读
目的:探讨肺表面活性物质(PS)珂立苏(Calsurf)对新生儿呼吸窘迫综合征(NRDS)的治疗效果。方法:将符合标准的52例患儿在给予相同综合治疗的基础上分为两组:治疗组(珂立苏)及对照组(不用珂立苏),比较两组NRDS临床呼吸机通气参数、机械通气时间、血气变化。结果:治疗组呼吸机通气参数、机械通气时间明显低于对照组,均有显著性改善(P<0.05);用药后,抽血气分析监测pH、氧分压(PaO2)及二氧化碳分压(PaCO2),其较用药前均显著性改善(P<0.05)。肺炎、肺出血、颅内出血并发症没有明显增加。结论:珂立苏能够显著提高NRDS疗效,使用安全。
Objective: To investigate the therapeutic effect of pulmonary surfactant (PS) Calsurf on neonatal respiratory distress syndrome (NRDS). Methods: Fifty-two children who met the standard were divided into two groups on the basis of the same comprehensive treatment: the treatment group (Ke Li Su) and the control group (without Ke Li Su), compared the ventilation parameters of NRDS clinical ventilator, Mechanical ventilation time, blood gas changes. Results: Ventilation parameters and duration of mechanical ventilation in the treatment group were significantly lower than those in the control group (P <0.05). After treatment, blood gas analysis was used to monitor the changes of pH, PaO2 and partial pressure of CO2 PaCO2), which was significantly improved compared with before treatment (P <0.05). Pneumonia, pulmonary hemorrhage, intracranial hemorrhage no significant increase in complications. Conclusion: Ke Li Su can significantly improve the efficacy of NRDS, safe to use.